Cargando…

Directed evolution of angiotensin‐converting enzyme 2 peptidase activity profiles for therapeutic applications

Angiotensin‐converting enzyme 2 (ACE2) has been investigated for its ability to beneficially modulate the angiotensin receptor (ATR) therapeutic axis to treat multiple human diseases. Its broad substrate scope and diverse physiological roles, however, limit its potential as a therapeutic agent. In t...

Descripción completa

Detalles Bibliográficos
Autores principales: Heinzelman, Pete, Romero, Philip A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10019445/
https://www.ncbi.nlm.nih.gov/pubmed/36794431
http://dx.doi.org/10.1002/pro.4597
_version_ 1784908030425432064
author Heinzelman, Pete
Romero, Philip A.
author_facet Heinzelman, Pete
Romero, Philip A.
author_sort Heinzelman, Pete
collection PubMed
description Angiotensin‐converting enzyme 2 (ACE2) has been investigated for its ability to beneficially modulate the angiotensin receptor (ATR) therapeutic axis to treat multiple human diseases. Its broad substrate scope and diverse physiological roles, however, limit its potential as a therapeutic agent. In this work, we address this limitation by establishing a yeast display‐based liquid chromatography screen that enabled use of directed evolution to discover ACE2 variants that possess both wild‐type or greater Ang‐II hydrolytic activity and improved specificity toward Ang‐II relative to the off‐target peptide substrate Apelin‐13. To obtain these results, we screened ACE2 active site libraries to reveal three substitution‐tolerant positions (M360, T371, and Y510) that can be mutated to enhance ACE2's activity profile and followed up on these hits with focused double mutant libraries to further improve the enzyme. Relative to wild‐type ACE2, our top variant (T371L/Y510Ile) displayed a sevenfold increase in Ang‐II turnover number (k (cat)), a sixfold diminished catalytic efficiency (k (cat)/K (m)) on Apelin‐13, and an overall decreased activity on other ACE2 substrates that were not directly assayed in the directed evolution screen. At physiologically relevant substrate concentrations, T371L/Y510Ile hydrolyzes as much or more Ang‐II than wild‐type ACE2 with concomitant Ang‐II:Apelin‐13 specificity improvements reaching 30‐fold. Our efforts have delivered ATR axis‐acting therapeutic candidates with relevance to both established and unexplored ACE2 therapeutic applications and provide a foundation for further ACE2 engineering efforts.
format Online
Article
Text
id pubmed-10019445
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-100194452023-04-01 Directed evolution of angiotensin‐converting enzyme 2 peptidase activity profiles for therapeutic applications Heinzelman, Pete Romero, Philip A. Protein Sci Full‐length Papers Angiotensin‐converting enzyme 2 (ACE2) has been investigated for its ability to beneficially modulate the angiotensin receptor (ATR) therapeutic axis to treat multiple human diseases. Its broad substrate scope and diverse physiological roles, however, limit its potential as a therapeutic agent. In this work, we address this limitation by establishing a yeast display‐based liquid chromatography screen that enabled use of directed evolution to discover ACE2 variants that possess both wild‐type or greater Ang‐II hydrolytic activity and improved specificity toward Ang‐II relative to the off‐target peptide substrate Apelin‐13. To obtain these results, we screened ACE2 active site libraries to reveal three substitution‐tolerant positions (M360, T371, and Y510) that can be mutated to enhance ACE2's activity profile and followed up on these hits with focused double mutant libraries to further improve the enzyme. Relative to wild‐type ACE2, our top variant (T371L/Y510Ile) displayed a sevenfold increase in Ang‐II turnover number (k (cat)), a sixfold diminished catalytic efficiency (k (cat)/K (m)) on Apelin‐13, and an overall decreased activity on other ACE2 substrates that were not directly assayed in the directed evolution screen. At physiologically relevant substrate concentrations, T371L/Y510Ile hydrolyzes as much or more Ang‐II than wild‐type ACE2 with concomitant Ang‐II:Apelin‐13 specificity improvements reaching 30‐fold. Our efforts have delivered ATR axis‐acting therapeutic candidates with relevance to both established and unexplored ACE2 therapeutic applications and provide a foundation for further ACE2 engineering efforts. John Wiley & Sons, Inc. 2023-04-01 /pmc/articles/PMC10019445/ /pubmed/36794431 http://dx.doi.org/10.1002/pro.4597 Text en © 2023 The Authors. Protein Science published by Wiley Periodicals LLC on behalf of The Protein Society. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Full‐length Papers
Heinzelman, Pete
Romero, Philip A.
Directed evolution of angiotensin‐converting enzyme 2 peptidase activity profiles for therapeutic applications
title Directed evolution of angiotensin‐converting enzyme 2 peptidase activity profiles for therapeutic applications
title_full Directed evolution of angiotensin‐converting enzyme 2 peptidase activity profiles for therapeutic applications
title_fullStr Directed evolution of angiotensin‐converting enzyme 2 peptidase activity profiles for therapeutic applications
title_full_unstemmed Directed evolution of angiotensin‐converting enzyme 2 peptidase activity profiles for therapeutic applications
title_short Directed evolution of angiotensin‐converting enzyme 2 peptidase activity profiles for therapeutic applications
title_sort directed evolution of angiotensin‐converting enzyme 2 peptidase activity profiles for therapeutic applications
topic Full‐length Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10019445/
https://www.ncbi.nlm.nih.gov/pubmed/36794431
http://dx.doi.org/10.1002/pro.4597
work_keys_str_mv AT heinzelmanpete directedevolutionofangiotensinconvertingenzyme2peptidaseactivityprofilesfortherapeuticapplications
AT romerophilipa directedevolutionofangiotensinconvertingenzyme2peptidaseactivityprofilesfortherapeuticapplications